Key Takeaways:
Law firm Kahn Swick & Foti has launched an investigation into Humacyte Inc.’s leadership following a disclosed delay in its U.S. Food and Drug Administration application review.
"KSF has commenced an investigation into Humacyte, Inc. (NasdaqGS: HUMA)," the firm announced in a statement attributed to partner and former Louisiana Attorney General, Charles C. Foti, Jr., Esq.
The investigation was triggered by Humacyte's August 9, 2024, announcement that the FDA would require additional time to complete its review of the company's Biologic License Application (BLA) for its acellular tissue product. The specific reasons for the delay were not detailed in the original company disclosure.
Shares of Humacyte fell 8.5% to $2.15 in afternoon trading. The investigation adds a layer of legal and financial uncertainty for the company, compounding investor concerns about the timeline for regulatory approval and commercialization of its lead product candidate.
The law firm's probe will examine whether Humacyte's officers and directors breached their fiduciary duties to shareholders in connection with the FDA delay and related disclosures. Such investigations often scrutinize the timing and content of corporate statements to determine if investors were adequately informed of material risks. Kahn Swick & Foti is known for investigating corporate malfeasance on behalf of shareholders.
The delay in the BLA review was a significant setback for Humacyte, a company focused on developing and manufacturing universally implantable bioengineered human tissues. The product under review is central to its near-term growth strategy.
This investigation creates a new headwind for the company, potentially leading to litigation costs and distracting management. For investors, the key catalyst remains any update from the FDA on a revised timeline for the BLA review, which is now uncertain.
This article is for informational purposes only and does not constitute investment advice.
